title: Targeting Mutant AKT in Cancer.
abstract: The results of a phase I basket trial suggest that the AKT1 E17K mutation is a valid therapeutic target. AZD5363, an investigational pan-AKT inhibitor, may benefit patients with a range of solid tumors bearing this genetic alteration.
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D004357:Drug Synergism; D004958:Estradiol / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077267:Fulvestrant; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D009360:Neoplastic Cells, Circulating / Q000187:drug effects; D057285:Precision Medicine; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000235:genetics; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D011743:Pyrimidines; D011758:Pyrroles; D000077267:Fulvestrant; D004958:Estradiol; C494918:AKT1 protein, human; D051057:Proto-Oncogene Proteins c-akt; C575618:capivasertib